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Abstract
Background:  Available  in vitro and  in vivo methods for verifying protein substrates for
posttranslational modifications via farnesylation or geranylgeranylation (for example,
autoradiography with 3H-labeled anchor precursors) are time consuming (weeks/months),
laborious and suffer from low sensitivity.
Results: We describe a new technique for detecting prenyl anchors in N-terminally glutathione S-
transferase (GST)-labeled constructs of target proteins expressed in vitro in rabbit reticulocyte
lysate and incubated with 3H-labeled anchor precursors. Alternatively, hemagglutinin (HA)-labeled
constructs expressed in vivo (in cell culture) can be used. For registration of the radioactive marker,
we propose to use a thin layer chromatography (TLC) analyzer. As a control, the protein yield is
tested by Western blotting with anti-GST- (or anti-HA-) antibodies on the same membrane that
has been previously used for TLC-scanning. These protocols have been tested with Rap2A, v-Ki-
Ras2 and RhoA (variant RhoA63L) including the necessary controls. We show directly that RasD2
is a farnesylation target.
Conclusion: Savings in time for experimentation and the higher sensitivity for detecting 3H-labeled
lipid anchors recommend the TLC-scanning method with purified GST- (or HA-) tagged target
proteins as the method of choice for analyzing their prenylation capabilities in vitro and in vivo and,
possibly, also for studying the myristoyl and palmitoyl posttranslational modifications.
Background
Prenylation is a lipid posttranslational modification
(PTM) of proteins at cysteine residues in the C-terminal
region [1-7]. The specific sequence environment recog-
nized by prenyltransferases consists either of the CaaX box
for farnesyltransferase (FTase) and geranylgeranyltrans-
ferase 1 (GGTase1) or C-terminal cysteines of Rab
GTPases in the case of geranylgeranyltransferase 2
(GGTase2). In all instances, the cysteine-containing
region must be preceded on the N-terminal side by
approximately 10 residues providing a generally polar,
flexible, so called linker segment without inherent confor-
mational preferences [7]. The anchor can be of farnesyl (3
isoprenyl units) or of geranylgeranyl (4 isoprenyl units)
Published: 28 February 2006
BMC Biochemistry2006, 7:6 doi:10.1186/1471-2091-7-6
Received: 30 September 2005
Accepted: 28 February 2006
This article is available from: http://www.biomedcentral.com/1471-2091/7/6
© 2006Benetka et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Biochemistry 2006, 7:6 http://www.biomedcentral.com/1471-2091/7/6
Page 2 of 15
(page number not for citation purposes)
type [8]. Targeting to cellular membranes [1,9] and medi-
ation of protein-protein interactions [10-16] are well doc-
umented biological functions associated with these lipid
anchors.
Members of the Ras family of GTPases are of particular
medical interest, as their mutational hyperactivation as
well as mutations of proteins lying upstream in their sign-
aling pathways are associated with various cancers [17-
24]. Several other CaaX proteins from the Rho family of
GTPases [25,26] and Rap1A [27] are involved in tumori-
genesis as well. Since their lipid modifications are essen-
tial for their biological function [10,28-31], inhibitors of
prenyltransferases (PTases), especially of FTase [32-34]
attracted the interest of pharmaceutical research as anti-
cancer drugs. Two such compounds made it to phase III
trials [35,36]. Furthermore, there is evidence that inhibi-
tors of prenylation may be useful in the treatment of other
diseases such as infestation with protozoa [6,37].
However, we are far from understanding the physiological
consequences of inhibiting FTase or GGTase1 in cells
since the lists of the respective substrates are essentially
not known. Only a few dozen proteins, including several
fungal lipopeptide pheromons [38,39] (e.g. a-mating fac-
tor of Saccharomyces cerevisiae [40,41]) as well as mamma-
lian proteins of the Ras superfamily of small GTPases [42],
the trimeric G proteins [43] and the nuclear lamins of type
A [44] and B [45], have been experimentally identified
and verified as substrates of specific prenyltransferases yet.
Given the critical role of the prenyl anchor for biological
function (both with respect to the occurrence of prenyla-
tion and to the dependence on anchor type), it is of grow-
ing interest to analyze the prenylation status of so far
uninvestigated proteins and to enlarge the list of proven
prenylated proteins. A recently developed sophisticated in
silico method [46] generates a high number of predicted
protein candidates for prenylation and, especially for twi-
light zone predictions, efficient methods for experimental
verification of prenylation are necessary.
The standard literature method for in vitro or in vivo anal-
ysis of selected candidates involves transcription/transla-
tion of a cloned construct and protein prenylation in the
presence of 3H-labeled lipid anchor precursors followed
by autoradiography/fluorography [47-49]. Necessary con-
trols involve mutations of the C-terminal cysteine
expected to be modified, prenyltransferase inhibitor
applications and/or exposition to precursors of alternative
prenyl anchors during the prenylation reaction. However,
the reportedly long exposure times (weeks/months) con-
tradict the need for several repetitions of the experiment.
Optimization of protein expression and incubation con-
ditions is typically not avoidable. In our own experience,
many attempts with the standard technology ended up
without reportable result; i.e., the signals in initial experi-
ments were often below the detection limit. Scientific lit-
erature research showed that rarely a lab has studied the
prenylation status of more than a single target, apparently
as a consequence of the tenacious methodology.
The problem of long exposure times for 3H-autoradiogra-
phy has prompted us to study a variety of chromato-
graphic and scintillation methods for developing a faster
and more sensitive test system. We found a solution using
a TLC linear analyzer for testing the prenylation of
selected protein targets. N-terminally GST-tagged proteins
were in vitro transcribed/translated and incubated with
3H-labeled anchor precursors. Such a quick in vitro screen
might also be useful for finding proteins that deserve the
effort for detailed in vivo studies. A similar approach can
be used in vivo, if HA-tagged target proteins are expressed
in cell culture supplemented by radioactive prenyl anchor
precursors. This new approach on the detection of weak
3H-signals is expected also to be helpful for monitoring
posttranslational modifications with similar 3H-labeled
anchors such as myristoyl or palmitoyl.
Results
Optimization of experimental parameters and analysis of 
the prenylation behaviour of the protein Rap2A
The proposed new procedure starts with a PCR-amplifica-
tion of the GST-Rap2A open reading frame (Genbank
accession of Rap2A BC070031) followed by in vitro tran-
scription and translation using rabbit reticulocyte lysate in
the presence of a 3H-labeled isoprenoid donor. The GST-
tagged target protein is purified utilizing glutathione
sepharose 4B beads and concentrated by precipitation
with acetone. The sample is subjected to SDS-page gel
electrophoresis and transferred to a nitrocellulose mem-
brane by electroblotting. Detection of incorporated radio-
active label is performed by scanning with the TLC
analyzer (scanning time: 20 minutes per lane). After-
wards, the amount of target protein is evaluated by West-
ern blotting with an anti-GST-antibody on the same
membrane.
Experiments with wildtype GST-Rap2A fusion protein and
[3H]mevalonic acid were performed using various reac-
tion times and amounts of radioactive label. The optimal
conditions we found were 20–40 µCi [3H]mevalonic acid
and at least four hours reaction time, which is in agree-
ment with previous studies [48].
Experiments with 20 µCi [3H]mevalonic acid, 10 µCi
[3H]farnesylpyrophosphate (FPP) and 10 µCi [3H]geran-
ylgeranylpyrophosphate (GGPP) allowed affirmation of
prenylation of Rap2A and identification of the preferred
isoprenoid attached to Rap2A as a farnesyl-group. How-
ever, geranylgeranylation did also occur under the givenBMC Biochemistry 2006, 7:6 http://www.biomedcentral.com/1471-2091/7/6
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conditions, but with much lower efficiency (Figure 1). The
respective peak area for FPP incorporation is about 15
times the one for GGPP integration. The mutated version
(C180A) was used as a negative control reaction to rule
out unspecific attachment and to confirm the location of
the modification.
All results obtained with our new method were consistent
with previously reported data on Rap2A [50], demonstrat-
ing the functionality of the assay. It should be noted that
the time consumption of the scanning procedure (1–2
hour per gel) is markedly reduced compared with autora-
diography (weeks-months). To allow direct comparison
of methods, a film has been exposed with the same West-
ern membrane used for detection with the TLC-Scanner
after application of En3Hance Spray from PerkinElmer for
one and for three weeks at -80°C. An exposure of three
weeks was necessary to get a distinct signal from all bands,
which had given a strong signal with the scanner. How-
ever, it wasn't sufficient to detect the low amount of GGPP
incorporated (Figure 2). If the expression of the target pro-
tein is lower than that of Rap2A, the autoradiography can
require months of exposure time.
To determine the enzyme prenylating Rap2A, we per-
formed the same assay with and without inhibitors of pre-
nyltransferases. The signal yielded by incorporation of
[3H]FPP was reduced to background level upon addition
of 50 µM of the FTase inhibitor FTI-277. In addition, the
already weak signal of [3H]GGPP-incorporation was
diminished to background level by FTI, while application
of a GGTase inhibitor (GGTI-298) left a small peak (Fig-
ure 3). These data suggest that Rap2A is recognized only
by FTase, but the enzyme can also transfer a geranylgera-
nyl-group, albeit with drastically reduced efficiency (1–2
orders of magnitude) as suggested before on the basis of
peptide substrate exposure to FTase [51].
Analysis of the in vitro prenylation of RasD2, v-Ki-Ras2 and 
RhoA63L with the TLC scanning method
These three candidates have been selected to show the
ability of our new technique to detect alternative prenyla-
tion modes. RasD2 (synonym: Rhes, BC013419) is sug-
gested to be a farnesylation target but only due to indirect
evidence [52]. Whereas K-Ras homologues such as v-Ki-
Ras2 (the Q61H oncogene mutant of K-Ras4B,
BC013572) are thought to be modified both by FTase and
Western blots and TLC scanning results for Rap2A with radioactive prenyl anchor precursors Figure 1
Western blots and TLC scanning results for Rap2A with radioactive prenyl anchor precursors. Western Blot and corre-
sponding scans from TLC linear analyzer of wildtype GST-Rap2A-fusion protein translated with [3H]mevalonic acid (lane 1), 
GST-Rap2A C180A with [3H]mevalonic acid (lane 2), GST-Rap2A with [3H]FPP (lane 3) and GST-Rap2A with [3H]GGPP (lane 
4). There is significant incorporation of a product of mevalonic acid (lane 1) as well as FPP (lane 3), while incorporation of 
GGPP is close to the detection limit (lane 4), suggesting that Rap2A is primarily a farnesylation target.
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GGTase1 [53], the RhoA protein (NM_001664.2) is pri-
marily a GGTase1 target [54].
The same in vitro assay was performed on all three targets.
Because of lower translation efficiency, the reaction mix
had to be upscaled by a factor of 5 for RasD2 and
RhoA63L and a factor of 7 for K-Ras4B compared with the
recipe used for Rap2A. For RasD2 and RhoA63L, we used
50 µCi of [3H]mevalonic acid and 25 µCi of [3H]FPP/
[3H]GGPP. In the case of v-Ki-Ras2, we applied 60 and 30
µCi respectively. The results for RasD2 were similar to
Rap2A with significant incorporation of a product of
mevalonic acid as well as FPP, while GGPP yielded only a
ca. 40 times weaker signal (as measured via area below
peaks, Figure 4). Thus, we have shown with direct argu-
ments that RasD2 is indeed a target for farnesylation [52].
On the contrary, while also showing preference for FPP,
incorporation of GGPP into v-Ki-Ras2 in the absence of
FPP is only 2–3 times lower (Figure 5). These results pro-
vide strong evidence for the hypothesis of alternative pre-
nylation while inhibiting FTase. RhoA yielded strong
signals for the reactions with mevalonic acid and GGPP
(Figure 6). The efficiency of FPP attachment is lower than
that with GGPP by a factor of 2. Since the amount of pro-
tein detected in the Western blot under condition of FPP
addition (lane 3) is considerably larger than in the case of
exposition to GGPP (lane 4), we suggest that GGPP is
Autoradiographs of Rap2A after exposure to radioactive prenyl anchor precursors Figure 2
Autoradiographs of Rap2A after exposure to radioactive prenyl anchor precursors. Fluorography of GST-Rap2A-fusion 
protein on a Western membrane after treatment with En3Hance-spray (2-methyl-naphtalene, Perkin-Elmer), showing a protein 
size marker in lane 1, wildtype GST-Rap2A translated with [3H]mevalonic acid in lane 2, GST-Rap2A C180A with [3H]meval-
onic acid in lane 3, GST-Rap2A with [3H]FPP in lane 4 and GST-Rap2A with [3H]GGPP in lane 5. A) film after exposure for 7 
days, B) film after exposure for 20 days at -80°C. There is no sign of incorporation of GGPP as detected with the TLC-scanner, 
underscoring the higher sensitivity of our new method. It should be noted that it is difficult to evenly spread the En3Hance-sub-
stance over all membrane area. Therefore, it is not surprising that the relative signal intensities are not identical between TLC 
scanning and autoradiography.
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indeed the preferred substrate. This is in accordance with
the literature that RhoA is geranylgeranylated [54] and K-
Ras can be modified by both isoprenoids [53].
Electrophoretic mobility shifts of in vivo prenylated 
proteins
The simplest in vivo test for prenylation is performed with
comparative electrophoretic shift analysis of non-pre-
nylated and prenylated protein forms. The differential
shift is typically not caused by the prenyl anchor attach-
ment itself but rather by the in vivo post-prenylation
processing steps such as subsequent palmitoylation, pro-
teolytic cleavage of the C-terminal tripeptide of the CaaX
box or C-terminal methylation. These mobility shifts are
generally small and not easily detectable for all proteins
due to their differential post-prenylation processing and
possible variable degradation of the prenylated and non-
prenylated forms.
Clear electrophoretic mobility shifts have been observed
for Rap2A providing an indirect argument for its far-
nesylation (Figure 7). In the case of the wild-type protein,
we see two bands corresponding to the non-farnesylated
(slow) and farnesylated (fast) forms (lane 1). As a result
of application of lovastatin (lane 2), the fast band repre-
senting the farnesylated Rap2A disappears (and the slow
band grows in intensity). This effect can be reversed by
application of growing amounts of exogenous FPP.
In vivo subcellular localization of N-terminally GFP-tagged 
constructs
To confirm the biological relevance of the results from our
in vitro assays, we analyzed the subcellular localization in
HeLa cells of the same proteins as N-terminal GFP-fusion
constructs. We tested the wildtype forms, the variants with
a mutation at the prenylation site and the wildtype forms
together with FTI and GGTI (Figure 8). Fluorescence
microscopic views of Rap2A and RasD2 expression
showed definite membrane localization for the wildtype
protein without and with GGTI. The mutant proteins and
the wildtype proteins treated with FTI mislocalized and
accumulated in the nucleus. A GFP-fusion protein of
RhoA63L, which has been shown to be a primary geran-
ylgeranylation target and which has been previously used
for localization studies [55], was used to demonstrate the
functionality of the GGTI treatment. Membrane localiza-
tion is observed for wildtype protein without and with
FTI, nuclear mislocalization is found for the mutant and
wildtype protein with GGTI. These observations agree
with the results from the in vitro prenylation assay.
Western blots and TLC scanning results for Rap2A incubated with prenyltransferase inhibitors Figure 3
Western blots and TLC scanning results for Rap2A incubated with prenyltransferase inhibitors. Western Blot and cor-
responding scans from TLC linear analyzer of wildtype GST-Rap2A-fusion protein translated with [3H]FPP (lane 1), with 
[3H]FPP and 50 µM FTI-277 (lane 2), with [3H]GGPP (lane 3), with [3H]GGPP and 50 µM FTI-277 (lane 4), and with [3H]GGPP 
and 50 µM GGTI-298 (lane 5). There is no incorporation of FPP with FTI (lane 2), and there is also no incorporation of GGPP 
with FTI (lane 4), while a hardly detectable signal remains with GGTI (lane 5), suggesting that Rap2A is recognized only by far-
nesyltransferase. However, the enzyme shows some cross-reactivity with GGPP.
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Further, we investigated the subcellular localization of the
GFP-v-Ki-Ras2 fusion protein in HeLa cells. As shown in
Figure 8 (part 9), fluorescence microscopy clearly revealed
that the fusion protein was co-localized with cellular
membranes. A GFP fusion construct harboring a Cys to
Ala mutation within the CaaX box predominantly accu-
mulated in the nucleus (Figure 8, part 10). When using
specific inhibitors of farnesylation (FTI-277) or of geran-
ylgeranylation (GGTI-298), we surprisingly found that v-
Ki-Ras2 was present mainly in the nucleus with FTI-277
(Figure 8, part 11), whereas GGTI-298 did not show any
affect on the localization of the fusion protein (Figure 8,
part 12).
In the literature, K-Ras4A and K-Ras4B have been reported
to be predominantly farnesylated in vivo. In the presence
of potent FTIs, both proteins were alternatively prenylated
by geranylgeranyltransferase-1 in the human colon carci-
noma cell line DLD-1 and COS cells [53]. Respectively, K-
Ras4A and K-Ras4B were found to be associated with the
membrane fraction independent of the kind of prenyla-
tion in COS cells. For complete inhibition of K-Ras4B pre-
nylation, a combination for FTI-277 and GGTI-298 was
required as examined in five different human carcinoma
cell lines from pancreatic, pulmonary, and bladder origins
[56]. The differing results can be due to differences in cell
lines, Ras substrates or GFP-v-Ki-Ras2 overexpression. In
the latter case, the ratio of prenylpyrophosphate to sub-
strate protein is skewed. Indeed, at high expression levels,
GFP-v-Ki-Ras2 was always found predominantly in the
nucleus, independent of the presence of FTIs, GGTIs or
the Cys-to-Ala mutation within the C-terminal CaaX box.
In support of our interpretation, Rilling et al. [57] reported
that protein prenylation in Chinese hamster ovary cells
can vary as a function of the extracellular mevalonate con-
centration. Fortunately, only for v-Ki-Ras2, we found the
localization studies to be technically tricky, fragile and the
results difficult to reproduce. Whereas cells were sensitive
for overexpression of wildtype GFP-v-Ki-Ras2 resulting in
low transfection efficiency and, consequently, the number
of transfected cells was low, no similar difficulties could
be observed for GFP-vi-K-Ras2 mutant C185A or any of
the other GFP-fusion constructs of RasD2, Rap2A or
RhoA.
Analysis of the in vivo prenylation of Rap2A with the TLC 
scanning method
It would be desirable to test whether the TLC scanning
method is applicable also for the investigation of protein
targets exposed to metabolic labelling with radioactive
Western blots and TLC scanning results for RasD2 with radioactive prenyl anchor precursors Figure 4
Western blots and TLC scanning results for RasD2 with radioactive prenyl anchor precursors. Western Blot and corre-
sponding scans from TLC linear analyzer of wildtype GST-RasD2-fusion protein translated with [3H]mevalonic acid (lane 1), 
GST-RasD2 C263A with [3H]mevalonic acid (lane 2), GST-RasD2 with [3H]FPP (lane 3) and GST-RasD2 with  [3H]GGPP (lane 
4). There is significant incorporation of a product of mevalonic acid (lane 1) as well as FPP (lane 3), while incorporation of 
GGPP is close to the detection limit (lane 4), suggesting that RasD2 is recognized primarily by the FTase. 
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precursors in vivo and purified with immunoprecipitation
from cell culture, SDS-page gel electrophoresis and West-
ern transfer. Since we expected the translation efficiency to
be critical for the success of the experiment, we selected
Rap2A as test target (Figure 9). Indeed, it was possible to
clearly show incorporation of radioactive FPP into Rap2A
overexpressed in HeLa cells and recovered by immunopre-
cipitation with anti-HA-antibodies (lane 1) and the
absence of the anchor in the C180A mutant treated iden-
tically (lane 2). It is especially notable that the amount of
purified protein can be evaluated with an anti-HA-anti-
body on the same Western blot that was used previously
for TLC-scanning similarly to the in vitro protocol with the
anti-GST-antibody.
Attempts to detect the prenylation status of Rap2A with 
HPLC-based purification methods
We have also attempted the proof of prenylation with
chromatographic methods. In one of these variants, we
utilized coupled in vitro transcription/translation and pre-
nylation. But labelling with 3H-marked isoprenoids was
replaced by usage of [35S]methionine during translation,
while the added isoprenoid was not radioactively marked.
Purification via GST-beads was performed in analogy to
the method described above but, after precipitation with
acetone, the protein was resuspended in a denaturation
buffer containing 50 mM Tris-HCl pH 8.0 as well as 4 mM
dithiothreitol (DTT) and 8 M urea. After denaturation, the
solution was diluted by addition of 10 volumes 50 mM
NH4HCO3. Following digestion with trypsin, the peptides
were separated using a C18 column in reverse phase
HPLC. Radioactivity was detected by scintillation count-
ing of the collected fractions after the UV signal was
recorded. Since the C-terminal peptide of Rap2A contains
a methionine residue, a radioactive signal should be
found at a retention time characteristic for farnesylated
peptides, while it should be absent for the C180A mutant,
because the non-prenylated peptide would elute much
earlier. Although the expected behavior was observed in
singular experiments, we have not been able to select
experimental conditions for the reproducible detection of
prenylated peptides (see discussion).
Discussion
The critical step in classical prenylation assays is the detec-
tion of the radioactive anchor with autoradiography/
fluorography. Unfortunately, the sensitivity of this
approach is weak since the 3H-labeled anchors emit low-
Western blots and TLC scanning results for v-Ki-Ras2 (K-Ras-4B) with radioactive prenyl anchor precursors Figure 5
Western blots and TLC scanning results for v-Ki-Ras2 (K-Ras-4B) with radioactive prenyl anchor precursors. Western 
Blot and corresponding scans from TLC linear analyzer of wildtype GST-v-Ki-Ras2-fusion protein translated with [3H]meval-
onic acid (lane 1), GST- v-Ki-Ras2 C185A with [3H]mevalonic acid (lane 2), GST-K-Ras with [3H]FPP (lane 3) and GST-K-Ras 
with [3H]GGPP (lane 4). There is incorporation of a product of mevalonic acid (lane 1) and FPP (lane 3) and also a reduced but 
noticeable amount of GGPP (lane 4), supporting the view of alternative geranylgeranylation of K-Ras in the absence of far-
nesylation.
0 50 100 0 50 100 0 70 140 0 70 140
Counts Counts Counts Counts
  kDa
250
148
60
42
30
22
17
6
4
K-Ras  wt
mevalonate
K-Ras  C185A
mevalonate
K-Ras  wt
FPP
K-Ras  wt
GGPP
1                                                                                          2                                                                                          3                                                                                       4                                                 BMC Biochemistry 2006, 7:6 http://www.biomedcentral.com/1471-2091/7/6
Page 8 of 15
(page number not for citation purposes)
energy radiation and the amount of purified protein with
attached anchor is typically very low before expression
and modification conditions have been optimized indi-
vidually for the specific target. The necessary exposure
time is a priori unknown and varies widely depending on
the target even after optimization of experimental condi-
tions. Several experimenters reported long exposure times
of up to several weeks (7 – 30 days [49], 3 – 14 days [48],
at least one week [58]). To confirm the efficiency of our
protocol, we did a comparison of our detection method to
a Western membrane treated with Perkin Elmer
"En3Hance-spray", which is the membrane equivalent to
a gel soaked in "Amplify" scintillation liquid, and found
weak signals after one week and distinct signals only after
three weeks (Figure 2, compared to Figure 1). TLC scan-
ning is an efficient alternative to autoradiography/fluor-
ography.
Even having a negative outcome after 2 months exposure
does not clarify whether the protein investigated cannot
be prenylated or whether the amount of protein after puri-
fication is simply too low, for example due to unspecific
adsorption to test tubes promoted by the prenyl anchor. It
should be noted that the issue is not resolved with a
[35S]methionine-based control of translation in a parallel
experiment. However, this problem is circumvented by
another advantage of the present protocol. It has the pos-
sibility to evaluate the amount of protein directly from the
Western blot that has been used for TLC scanning. If a
band is detected with low intensity of anti-GST- or anti-
HA-antibody binding, this indicates that the expression of
the target protein must be up-scaled.
Filter binding assays (i.e., the separation of proteins tran-
scribed and translated in vitro in the presence of radioac-
tive anchor precursors from free anchors with filters)
provide another quick alternative to autoradiography. The
information from such a test is limited since there is no
size resolution of the protein mixture and no possibility to
directly evaluate the amount of target protein. Further-
Western blots and TLC scanning results for RhoA63L with radioactive prenyl anchor precursors Figure 6
Western blots and TLC scanning results for RhoA63L with radioactive prenyl anchor precursors. Western Blot and cor-
responding scans from TLC linear analyzer of wildtype GST-RhoA63L-fusion protein translated with [3H]mevalonic acid (lane 
1), GST-RhoA63L mutant C190S with [3H]mevalonic acid (lane 2), GST-RhoA63L with [3H]FPP (lane 3) and GST-RhoA63L 
with [3H]GGPP (lane 4). There is significant incorporation of a product of mevalonic acid (lane 1) as well as of GGPP (lane 4). 
The signal for FPP attachment is reduced, although more protein is detected (lane 3). This confirms GGPP as preferred sub-
strate.
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more, free radioactive anchors will non-specifically
adsorb to the filter material or proteins resulting in high
background signals.
To our knowledge, the current method is the first one uti-
lizing a TLC-Scanner for the analysis of putative targets of
PTases on Western blot membranes. Compared to autora-
diography/fluorography, this approach reduces the detec-
tion time from several weeks/months to 20 minutes per
lane, resulting in an overall time effort for the whole
experiment of about three days, given that the cDNA of
the GST- (or HA-tag-) fusion protein is already available.
Additionally, this assay detects incorporated 3H-label and
translation efficiency of the same reaction, rendering con-
trol reactions with [35S]methionine redundant and reduc-
ing variability of results caused by pipetting inaccuracies.
In conclusion, the TLC scanning method is more sensitive
and offers a more reliable way of quantification of any
covalently linked 3H-labeled posttranslational modifica-
tions in much less time compared with autoradiography.
Especially, when conditions for in vitro or in vivo protein
expression and incubation still need to be set up or opti-
mized, this method dramatically enhances chances of
generating successfully generating reproducible results in
reasonable time since the experimental cycle is considera-
bly shortened.
The use of a GST-tag (or a HA-tag) provides a way of
removing free radioactive label as well as separation from
highly abundant proteins from the rabbit reticulocyte (in
vitro test) or cell culture lysate (in vivo test), resulting in
lower background signal. In addition for proteins with
lower translation efficiency than Rap2A, it offers the
opportunity to use bigger reaction volumes or larger cell
cultures and load the whole yield on a gel without exceed-
ing its capacity. Furthermore, it provides the opportunity
to use the same primers and antibodies for all investigated
proteins, making the adaptation of the assay to screening
with higher throughput only a small step.
We have shown that the results obtained with our TLC
scanning method are in line with those from parallel
experiments testing electrophoretic mobility shifts (Figure
7) or subcellular localization changes (Figure 8) due to
prenyl anchor attachment. It should be emphasized that
the latter two methods are indirect and leave room for
alternative interpretations whereas our assays based on
TLC scanning provide a much stronger argument. It une-
quivocally shows anchor incorporation into the target
protein directly in vitro as well as in vivo.
Unfortunately, we were not able to find any conditions,
which reproducibly allowed detection of the prenylated
peptide with HPLC-based purification methods after pro-
teolytic digest. Most of the times, there was no visible dif-
ference between wildtype and mutant Rap2A in UV-
signals as well as radioactivity measurements, except the
fact that the total peptide content was significantly (ca. 3
times) higher for the mutant protein. These findings sug-
gest that, in contrast to the non-prenylated protein, a con-
siderable amount of prenylated protein is lost by
unspecific adsorption to the walls of the Eppendorf tubes,
vials, tubes and microwell plates used for the reaction and
following processing steps. This is in agreement with our
observation from the Western blots of the TLC scanning
method (Figures 1, 2, 3, 4, 5, 6 and 9), which in almost all
cases showed much higher protein content for the non-
prenylatable mutant proteins. Additionally, we derived
much better results when performing reaction and purifi-
cation steps the same day, storing the samples in SDS-
PAGE sample buffer at -20°C over night. Storage of the
protein in the reaction mix or in PBS without detergent
resulted in decreased radioactive signals. From these
observations, we suggest that there would be even higher
losses of the prenylated peptide after digestion, since the
properties of the shorter polypeptide are much more
dominated by the hydrophobic isoprenoid group, leaving
Mobility changes of the prenylated protein form: Immunoblot  analysis of Rap2A Figure 7
Mobility changes of the prenylated protein form: Immu-
noblot analysis of Rap2A. Western blot analysis has been 
performed on lysates of exponentially growing cells. U 
denotes the unmodified, P the prenylated form of Rap2A. A) 
HeLa cells have been transiently transfected with HA-Rap2A 
(lanes 1–4). Upon treatment with lovastatin (lane 2), the sig-
nal representing prenylated (p) Rap2A disappeared. This 
effect could be reversed by adding FPP (lanes 3 and 4), but 
not by adding GGPP (data not shown). B) HeLa cells have 
been transiently transfected with HA-Rap2A (lanes 2 and 3) 
or HA-Rap2A with a cysteine-to-alanine mutation within the 
C-terminal CAAX prenylation motif (lane 1, mutation 
C180A). The mutation and also the lovastatin treatment pre-
vent the prenylation of HA-Rap2A.
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only undetectable amounts of labeled prenylated peptide
in solution.
These problems show that the chromatographic method
might not be applicable for the small amounts of protein
yielded by in vitro transcription/translation. There might
be the possibility to overcome most of the troubles by
simply increasing the amount of target protein. Results
obtained with Rap2A expressed in HeLa-cells, purified by
immunoprecipitation and digested with trypsin showed
significant discrepancy between the UV-signals of
wildtype and mutant protein (data not shown). One peak
with a retention time close to the one of FPP had a peak
area ~10 times larger for wildtype protein, while all other
Localization of N-terminal GFP-constructs of Rap2A, RasD2, v-Ki-Ras2 and RhoA63L in HeLa cells Figure 8
Localization of N-terminal GFP-constructs of Rap2A, RasD2, v-Ki-Ras2 and RhoA63L in HeLa cells. HeLa cells were 
analysed by fluorescence microscopy after transfection with the following constructs: inserts 1, 3 and 4 – GFP-Rap2A; insert 2 
– GFP-Rap2A C180A; inserts 5, 7 and 8 – GFP-RasD2; insert 6 – GFP-RasD2 C263A; inserts 9, 11 and 12 –GFP-v-Ki-Ras2; 
insert 10 – GFP-v-Ki-Ras2 C185A; inserts 13, 15 and 16 – GFP-RhoA63L; insert 14 – GFP-RhoA63L C190S. Nuclei were co-
stained with DAPI (blue color).   
A) GFP-Rap2A, GFP-RasD2 and GFP-v-Ki-Ras2 are membrane-localized with (4, 8, 12) or without (1, 5, 9) GGTI-298 treat-
ment. Mutation of the Cys in the CaaX box (2, 6, 10) or treatment with FTI-277 (3, 7, 11) cause mislocalization and accumula-
tion of the fusion proteins in the nucleus.   
B) GFP-RhoA is membrane localized with (15) or without (13) FTI-277 treatment. Mutation of the Cys in the CaaX box (14) or 
treatment with GGTI-298 (16) cause mislocalization and accumulation of RhoA in the nucleus.   
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peaks were nearly identical. Based upon these promising
preliminary experiments, future work may find a mass
spectrometry-coupled HPLC-based approach useful for in
vivo prenylation analysis.
We think that the mechanistic role of the prenyl anchor
for the biological function of the proteins studied in this
work still requires additional research. For the conven-
ience of the reader, we summarize the current state of
knowledge with respect to the molecular and cellular
functions of the investigated protein targets for prenyla-
tion in the following four paragraphs. Apparently, Rap2A,
RasD2, K-Ras and RhoA need the prenyl anchor to get
translocated into the right signaling context by membrane
association. Rap2 has been shown to promote integrin
activation [59] and to directly bind to the actin cytoskele-
ton of platelets [60]. Rap2A is regulated by the same GEFs
and GAPs as Rap1, but with much lower efficiency for the
GAPs. This results in a high ratio of GTP-bound protein.
Rap2 may be a slow molecular switch with functions sim-
ilar to Rap1, but while the latter transduces strong, tran-
sient signals, Rap2A could determine the basal level. Thus,
Rap1 would be required in the initial step of cell adhe-
sion, which is then maintained by Rap2 signaling [61].
RasD2/Rhes (ras homolog expressed in striatum) is
expressed predominately in the striatum [62] but also in
thyroid glands and pancreas β-cells [63]. It is involved in
selected stritial functions, mainly locomotor activity and
motor coordination [64]. Unlike the Ras proteins, RasD2
does not activate the ERK-pathway, but it binds and acti-
vates phosphoinositide 3-kinase (PI3K). Additionally,
RasD2 impairs activation of cAMP/PKA pathway by thy-
roid stimulating hormone (THS), as well as by activated
β2-adrenergic receptor, suggesting a regulating function
upstream of activation of the respective heterotrimeric G-
protein complex. The mechanism of action implies
uncoupling of the receptor from its downstream target
[52].
The Ras proteins have been reported to be involved in
many signaling pathways, regulation cell differentiation
and proliferation as well as cell shape and motility, to
mention only the most important. Ras proteins are
GTPases that function as molecular switches, being active
in GTP-bound state and inactive when GDP-bound. The
different Ras proteins show high homology to each other
and collaborate in a complex network, making it hard to
distinguish whether their functions are provided by all of
them or are unique for a certain type of Ras protein. Nev-
ertheless, there is some experimental data indicating spe-
cific functions of K-Ras4B in cell-cell and cell-matrix
contacts as well as in apoptosis [65]. These presumptions
are supported by the fact that K-Ras4B has a different strat-
egy for membrane association than H-Ras, N-Ras and K-
Ras4A, with a polylysine stretch in the hypervariable
region instead of cysteine residues as palmitoylation sites.
This comes along with localization of K-Ras4B to different
microenvironments of membranes and also a trafficking
pathway different from the other Ras proteins [66].
In humans, there are three highly homologous isoforms
of Rho GTPases, called RhoA, B and C [67]. Similar to the
Ras proteins, their activities are highly overlapping,
explaining why reported functions are hardly ever
assigned to a certain family member. Regulation of the
actin cytoskeleton, particularly the formation of stress fib-
ers, was the first reported function of Rho. Further investi-
gations have revealed roles in the regulation of cell
polarity, gene transcription, G1 cell cycle progression,
microtubule dynamics and vesicular transport pathways
[68]. Thus, it seems that Rho proteins play a major role in
vital cell functions such as morphogenesis, chemotaxis,
axonal guidance and cell cycle progression [69].
Conclusion
Savings in time for experimentation and the higher sensi-
tivity for detecting 3H-labeled lipid anchors recommend
the TLC-scanning method with GST-tagged or HA-tagged
target proteins as the method of choice for analyzing their
Western blots and TLC scanning results for Rap2A with radi- oactive FPP in vivo Figure 9
Western blots and TLC scanning results for Rap2A with 
radioactive FPP in vivo. Western Blot and corresponding 
scans from TLC linear analyzer of wild-type HA-Rap2A-
fusion protein (lane 1) and HA-Rap2A C180A (lane 2) immu-
noprecipitated from HeLa-cells, treated with lovastatin after 
transfection with the respective plasmid construct and 
exposed to 3H-FPP. There is significant incorporation of FPP 
into the wild-type protein (lane 1), but no signal is detected 
for the C180A mutant (lane 2), demonstrating the applicabil-
ity of the approach for in vivo labeling experiments.
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prenylation capabilities in vitro and in vivo and, possibly,
also for studying the myristoyl and palmitoyl posttransla-
tional modifications.
Methods
Construct production and cloning
We generated plasmids containing GST- and pEGFP-
fusions of all genes studied in this work. The cDNAs of
Rap2A (IMAGE clone ID IMAGp998M0310712, Genbank
accession BC070031), RasD2 (IMAGp958D21250,
BC013419), v-Ki-Ras2B (IMAGp998J059643Q1,
BC013572) and the open reading frame coding for
RhoA63L (provided as pEGFP C1-vector by C. J. Der, UNC
USA; in contrast to the wild type form, this mutant is per-
manently activated and is able to induce malignant trans-
formation of cells [55]) were cloned into the pGEX5X1-
vector (pGEX4T1 for RhoA63L), thereby creating N-termi-
nal GST-fusion proteins. The Stratagene QuikChange XL
Site-Directed Mutagenesis Kit was used to introduce
cysteine-to-alanine mutations in the CaaX-motifs. Since
this residue is the site of covalent thioether linkage of the
isoprenoid modification, the ability to become modified
should be abolished. For RhoA63L, the already available
cysteine-to-serine mutant (cloned into the pEGFP C1-vec-
tor as supplied by C. J. Der, UNC USA) has been used. N-
terminal GFP-fusion proteins were used to investigate the
subcellular localization in transiently transfected HeLa-
cells. Therefore, both wildtype and mutant cDNA of
Rap2A, RasD2, and v-Ki-Ras2 were also cloned into the
pEGFP C2-vector.
In vitro prenylation assay
The cDNA of the GST-fusion proteins was amplified by
PCR using standard conditions. A 5'-primer has been
designed especially for in vitro transcription/translation,
containing a promoter, a Kozak-Consensus-sequence and
an annealing sequence for the GST-tag: 5'
gcgtaatacgactcactatagggagaccaccatgtcccctatacttaggttattgg 3'
A 3'-primer sequence 5' agatcgtcagtcagtcacgat 3' has been
designed to anneal in the pGEX5X1-vector downstream of
the insert, allowing the use of the same primer pair for all
proteins. All oligonucleotides used were synthesized by
MWG Biotech. The radioactive label of choice (typically,
20 µCi [3H]mevalonic acid, 10 µCi [3H]FPP or [3H]GGPP,
all purchased from American Radiolabeled Chemicals)
was dried in a speedvac under vacuum at room tempera-
ture to remove the solvent, since ethanol could disrupt the
transcription/translation reaction. 20 µl rabbit reticulo-
cyte lysate, 0.5 µl PCR-Enhancer, 0.5 µl methionin (all
supplied with the Promega TNT Quick Coupled Tran-
scription/Translation Kit) and 2.5 µl of the PCR-reaction
were added, mixed and incubated at 30°C for 4 hours. For
experiments with inhibitors of prenyltransferases, the
whole mixture including 50 µM of the appropriate inhib-
itor, but without the DNA, was incubated for 30 min on
ice. Then, the reaction was started by addition of DNA.
The following steps were identical in all experiments. Dur-
ing the incubation of the reaction mixture, 50 µl glutath-
ione sepharose 4B-beads (75% slurry, from Amersham
Biosciences) were separately resuspended in 0.5 ml PBS
and spun down in a microcentrifuge at 1.600 rpm for one
minute. The supernatant was removed and the washing
step repeated once to equilibrate the beads for protein
binding. The whole TNT-reaction-mix and PBS to a final
volume of 200 µl was added. After resuspension, the
beads were incubated with gentle agitation at room tem-
perature for 1 hour. Afterwards, they were washed 5 times
with 0.5 ml PBS. Following the last washing step, 50 µl of
elution buffer (10 mM reduced glutathione in 50 mM
Tris-HCl, pH 8.0) were added and incubated again for 1
hour with agitation. The beads were spun down, the
supernatant transferred to a fresh vial and the protein pre-
cipitated by addition of 0.5 ml ice-cold acetone. The mix-
ture was spun at 10.000 rpm for 1 minute. The
supernatant was carefully decanted and the pellet air-
dried for 10 minutes.
The pellet was re-suspended in sample buffer, incubated
at 80°C for 10 min and resolved by SDS-PAGE (15%).
The protein was transferred from the gel to a nitrocellu-
lose membrane by electroblotting. The membrane was left
to dry. Each lane was scanned separately for 20 min using
a Berthold TLC linear analyzer LB 282. The spatial resolu-
tion of the scanner allows to assign each signal to a certain
protein size. Following this measurement, the membrane
was blocked with 10% milk powder in PBS. After incuba-
tion with primary antibody (anti-GST-antibody from rab-
bit, 1:5000) and secondary antibody (ECL Anti-rabbit
IgG, Horseradish peroxidase linked whole antibody from
donkey purchased from Amersham Biosciences,
1:10.000), addition of ECL plus Western Blotting Detec-
tion solution and exposure of a Hyperfilm ECL (both
from Amersham Biosciences) for 15 seconds, a band at a
molecular weight corresponding to the signals measured
by the TLC analyzer is detectable.
Determination of differential electrophoretic mobility 
after expression in cell culture
For N-terminal tagging, the ORFs of Rap2A (wild-type)
and the Rap2A C180A mutant form were cloned into the
plasmid pCIneo-HA [70]. HeLa cells were cultured on 6-
well plates in DMEM/10% FCS to 50% confluency. We
transiently transfected the cells with 1 µg DNA using Lipo-
fectamine Reagent and Plus Reagent (Life Technologies)
according to the manufacturers manual. After 3 hours of
incubation, the transfection medium was replaced by
fresh DMEM/10% FCS with or without 50 µM Lovastatin
(Sigma). For analyzing the effect of a FPP gradient, two
samples with either 2 µM or10 µM FPP have been pre-
pared.BMC Biochemistry 2006, 7:6 http://www.biomedcentral.com/1471-2091/7/6
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Ca. 16 hours later, extracts were prepared with lysis buffer
(50 mM Hepes, 140 mM NaCl, 1 mM EDTA, 1% (v/v) Tri-
ton X-100, 0.1% (w/v) Sodium Deoxycholic acid, Com-
plete Protease Inhibitor Cocktail (Roche)). Before loading
the samples onto a 16% SDS Gel, the extracts were centri-
fuged for 10 minutes at 13000 rpm using a table top cen-
trifuge and the supernatants boiled with sample buffer for
5 minutes. The proteins were transferred to nitrocellulose
membranes and probed with mouse anti-HA 12CA5 anti-
bodies and HRP-conjugated secondary antibodies.
Determination of intracellular localization
HeLa cells were plated at low density on coverslips. Then,
they were transfected with GFP-expression vectors carry-
ing the cDNA's of Rap2A, RasD2, v-Ki-Ras2 and RhoA63L
using Lipofectamine and Plus Reagent in serum-free
medium (Life Technologies) for 3.5 h. After washing, the
cells were maintained in growth medium for 14 h. Cells
were rinsed with PBS, fixed in 2% formaldehyde in PBS
for 20 min, washed with PBS, permeabilized with 0.1%
Triton X-100 in PBS for 10 min, washed with PBS and
mounted in vectashield (vector laboratories) for direct flu-
orescence of GFP. The effect of farnesylation or geran-
ylgeranylation inhibitors was assessed by treatment of the
cells with FTI-277 (10 µM) or GGTI-298 (5 µM) (Sigma)
during maintenance in growth medium for 14 h. Cells
were observed using an Axiplan 2 Imaging Microscope
(Zeiss). GFP- as well as DAPI-images were acquired with a
Coolsnap HQ camera (Photometrics) and analyzed using
the software Metamorph 6.2r4 (Universal Imaging
Corp.).
In vivo prenylation assay with HA-tag-based 
immunoprecipitation from cell culture and Western blot 
TLC scanning
Transfection and labelling
For N-terminal tagging, the ORFs of Rap2Awt and
Rap2AC180A were cloned into the plasmid pCIneo-HA
[70]. HeLa cells were cultured on 6 well plates in DMEM/
10% FCS to 50% confluency. We transiently transfected
the cells with 1 µg DNA using Lipofectamine Reagent and
Plus Reagent (Life Technologies) according to the manu-
facturers manual. After 3 hours of incubation, the trans-
fection medium was replaced by DMEM/10% FCS/30 µM
Lovastatin (Sigma). Four hours later, the medium was
replaced by DMEM/10% FCS/30 µM Lovastatin (Sigma)
containing 400 µCi 3H-FPP (ARC).
Immunoprecipitation
After ca. 16 hours, extracts were pre-cleared with Dyna-
beads M-280 Sheep anti-Mouse IgG (Dynal) in lysis buffer
(50 mM Hepes, 140 mM NaCl, 1 mM EDTA, 1% (v/v) Tri-
ton X-100, 0.1% (w/v) Sodium Deoxycholic acid, Com-
plete Protease Inhibitor Cocktail (Roche)) at room
temperature for 3 hours. Immunoprecipitation was per-
formed with mouse anti-HA 12CA5 antibodies
crosslinked to magnetic Dynabeads M-280 Sheep anti-
Mouse IgG (Dynal) at 4°C over night. We washed the
beads 3 times with lysis buffer and twice with lysis buffer
containing 500 mM NaCl. Before loading the samples
onto a 10 % SDS Gel, the beads were boiled in sample
buffer for 5 minutes. The proteins were transferred to
nitrocellulose membranes and monitored for incorpora-
tion of 3H-FPP anchors by TLC analysis. Subsequently, we
probed the Western blots with mouse anti-HA 12CA5
antibodies and HRP-conjugated secondary antibodies.
Magnetic beads were washed three times with TBS-T
(0.01% Triton X-100) and incubated with mouse anti-HA
12CA5 crude serum at 4°C over night.
Crosslinking to beads
The beads were again washed 3 times with TBS-T and 3
times with 0.2 M Sodiumborate pH 9.0. We crosslinked
beads and antibodies with 20 mM DMP in 0.2 M Sodium-
borate pH 9.0 for 15 minutes at room temperature.
Finally, the beads were washed 3 times for 15 minutes
with 1 M Tris pH 8.0 and 3 times with TBS-T.
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